• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthHealth

Patients are so sick and tired of waiting years for a transplant that they’re signing up in droves to receive vital organs from pigs

By
Lauran Neergaard
Lauran Neergaard
and
The Associated Press
The Associated Press
Down Arrow Button Icon
By
Lauran Neergaard
Lauran Neergaard
and
The Associated Press
The Associated Press
Down Arrow Button Icon
December 17, 2024, 10:09 AM ET
A genetically modified pig chews on a chain in a cage
On a farm in the southern US state of Virginia, David Ayares and his research teams are breeding genetically modified pigs to transplant their organs into human patients. Revivicor, the biotech company Ayares leads, is at the forefront of xenotransplantation research -- the implantation of animal organs into humans -- which aims to solve a chronic organ shortage that has thousands of Americans dying each year. Andrew Caballero-Reynolds / AFP—Getty Images

LOUISVILLE, Ky. (AP) — The calls and emails started coming into NYU Langone Health and Massachusetts General Hospital soon after doctors began experimenting with pig organs in humans.

Recommended Video

People worried they’ll never get a scarce human transplant asked: When could we get a pig kidney?

Alex Berrios of Louisville, Kentucky, needs a second transplant but finding another human match is proving impossible. So he’s closely watching for a chance at pig kidney research.

“It may not work, and I have to be OK with that,” Berrios said. “I think it’s worth the shot.”

Now two U.S. companies aim to begin the world’s first clinical trials of xenotransplantation in 2025 – using pig kidneys or hearts to try to save human lives. Would-be volunteers are impatient to see if they’ll qualify as researchers fine-tune how best to test if the humanized pig organs they’ve designed might really work.

Anticipation is growing with news that an Alabama woman was faring well after a pig kidney transplant at NYU in late November. Towana Looney is the fifth American to receive a gene-edited pig organ, each case so far an emergency experiment for people out of options.

None of the previous recipients — two given pig hearts and two kidneys — survived more than two months but that hasn’t deterred researchers hunting an alternative to the dire shortage of transplantable organs.

“We have to have the courage to continue,” said University of Maryland transplant surgeon Dr. Bartley Griffith.

Patients are driving the quest for pig organ transplants

Back in 2022, Griffith had a hard time figuring out how to ask a dying patient if he’d consider undergoing the world’s first transplant of a gene-edited pig heart.

“I was so afraid to mention the word pig heart,” Griffith said. He marveled that patient David Bennett responded with a joke about oinking and made clear if the last-ditch attempt failed that “maybe you’ll learn something for others like me.”

Fast forward to late 2023, when patients at a National Kidney Foundation meeting with FDA officials and pig developers described a life so miserable on dialysis that they, too, would chance an animal organ.

“Why not try? That was really what we took back,” said Mike Curtis, CEO of eGenesis, one of the companies developing organs. “It was like we really almost have an obligation to try.”

“The patients pushed us to go ahead,” agreed Dr. Tatsuo Kawai, a Mass General surgeon who’d been reluctant to even broach the idea – but last March, four months after that meeting, gave a longtime patient the first gene-edited pig kidney.

Sick and tired from dialysis, patients raise their hands for pig kidneys

In Palm Springs, California, Carl McNew emailed NYU to ask about volunteering while he’s still fairly healthy.

McNew donated a kidney to his husband in 2015 but later his remaining kidney began declining, something very rare in living donors. Medications and intermittent dialysis are helping but McNew knows he’ll eventually need a transplant.

“There’s just something about being part of something like that, that is so cutting-edge,” said McNew, who spotted news of NYU’s xenotransplant research in 2023 and emailed his interest.

For Louisville’s Berrios, donor scarcity isn’t the only hurdle. Born with a single kidney that failed in his late 20s, a living donor transplant restored his health for 13 years. But it failed in 2020 and he has since developed antibodies that would destroy another human kidney, what doctors call “highly sensitized.”

Every Monday, Wednesday and Friday, Berrios quietly slips out of his home before dawn to spend nearly four hours tethered to a dialysis machine. Getting the grueling treatments at 5 a.m. is the only way the father of two can both stay alive and hold down a fulltime job.

But dialysis doesn’t fully replace kidney function – people slowly get sicker. So even as Berrios tried an experimental therapy to tamp down his problem antibodies, he told NYU he’s interested in a pig kidney.

Expected soon: Rigorous trials testing pig organ transplants

FDA rules require that pig organs be extensively tested in monkeys or baboons before humans. And while researchers have extended those primates’ survival to a year, sometimes longer, they were desperate for experience with people. After all, the pig organs are genetically altered to be more humanlike, not more baboon-like.

At NYU and the University of Alabama at Birmingham, surgeons first tested pig organs in bodies of the recently deceased, donated for scientific research.

And patients given pig organs so far have been “compassionate use” transplants, experiments that FDA allows in select emergency cases for people out of other options.

Although the first four didn’t survive long, in part because of complications from other diseases, those experiments proved pig organs could work at least for a while and offered other lessons. For example, discovery of a hidden pig virus in the first heart transplant prompted better tests for that risk.

Only rigorous studies comparing similarly ill patients will offer a clearer picture of pig organs’ potential – maybe those like Looney. Despite eight years of dialysis, she wasn’t nearly as sick as prior xenotransplant recipients but couldn’t find a matching donor. Like Berrios, she had a highly sensitized immune response.

Looney may be “kind of a litmus test” for trial candidates, said NYU’s Montgomery, who led her transplant with her original surgeon in Alabama, Dr. Jayme Locke. “She’s received the transplant at just the right time,” before dialysis did too much damage.

What gene edits produced the best pig organs for human transplant?

Scientists have tried animal-to-human transplants for years without success but now they can edit pig genes, trying to bridge the species gap enough to keep the human immune system from immediately attacking the foreign tissue. Still, nobody knows the best gene combination.

Revivicor, a United Therapeutics subsidiary, produces kidneys and hearts with 10 gene edits, “knocking out” pig genes that trigger hyper-rejection and excessive organ growth and adding some human genes to improve compatibility. Maryland used hearts with 10 gene edits in its two xenotransplants. Looney also got a kidney with 10 gene edits, based on Locke’s research when she worked in Alabama.

While Montgomery is thrilled with Looney’s progress, he’s done most work using Revivicor pigs with just one gene edit, in a xenotransplant last April and in research with the deceased.

“Our feeling is, you know, less is more,” said Montgomery, noting it’s easier to mass produce pigs with fewer gene alterations. Looney’s transplant offers a chance to compare “really how much difference those additional gene edits are making.”

In Boston, eGenesis has still another approach – a whopping 69 gene edits. In addition to 10 genetic alterations to improve human compatibility, genes linked to certain pig viruses also are inactivated.

Pig organ transplants still have much to prove

Researchers feel pressure to show if pig organs can keep people alive much longer than a few months, said eGenesis’ Curtis. If not, the question will be “do we have the right gene edits?”

The balance is choosing participants sick enough to qualify but not so sick they have no chance.

“There’s a tremendous number of patients who would be very willing, very willing to do this,” said Dr. Silke Niederhaus of the University of Maryland, who isn’t involved in xenotransplant research but watches it closely.

Niederhaus became a kidney transplant surgeon because around her 12th birthday, one saved her life. That kidney lasted three decades. When it failed, it took five years to find another. So she understands the draw of pig research, and urges people to learn their odds of getting a human kidney before volunteering.

If they’re younger, healthier or have a living donor, “I would probably say go with what’s known and what’s proven,” Niederhaus said. But if they’re older and dialysis is starting to fail, “maybe it’s worth taking the risk.”

The Fortune 500 Innovation Forum will convene Fortune 500 executives, U.S. policy officials, top founders, and thought leaders to help define what’s next for the American economy, Nov. 16-17 in Detroit. Apply here.
About the Authors
By Lauran Neergaard
See full bioRight Arrow Button Icon
By The Associated Press
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

hoskins
Commentaryoffices
Gensler Co-Chair: Hot-desking was supposed to save money. It may be costing you your culture
By Diane HoskinsApril 30, 2026
3 hours ago
raw milk
Politicsmilk
Risk of paralysis, bacteria, even death is no match for Americans’ thirst for raw milk
By Laura Ungar, Jonel Aleccia and The Associated PressApril 29, 2026
18 hours ago
The Best Protein Shakes of 2026: Tasted and Approved by Nutrition Experts
HealthDietary Supplements
The Best Protein Shakes of 2026: Tasted and Approved by Nutrition Experts
By Christina SnyderApril 29, 2026
1 day ago
aging
HealthLongevity
We’re the CEOs of Peloton and the Hospital for Special Surgery. Living longer isn’t enough, we need to live better, too
By Bryan T. Kelly and Peter SternApril 29, 2026
1 day ago
AI is changing who gets to be an expert. Are your colleagues ready to become ‘directors of intelligence’?
AIProductivity
AI is changing who gets to be an expert. Are your colleagues ready to become ‘directors of intelligence’?
By Bruce BroussardApril 29, 2026
1 day ago
Robert F. Kennedy Jr. sits at a cafeteria table with schoolchildren.
EconomyEducation
More than two-thirds of U.S. schools say they’re unable to afford the cost of student free lunch—and MAHA’s dietary guidelines may make it worse
By Sasha RogelbergApril 29, 2026
1 day ago

Most Popular

Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
Success
Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
By Preston ForeApril 27, 2026
3 days ago
Jamie Dimon gets candid about national debt: ‘There will be a bond crisis, and then we’ll have to deal with it’
Economy
Jamie Dimon gets candid about national debt: ‘There will be a bond crisis, and then we’ll have to deal with it’
By Eleanor PringleApril 29, 2026
1 day ago
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
AI
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
By Sasha RogelbergApril 28, 2026
2 days ago
‘They left me no choice’: Powell isn’t going anywhere—blocking Trump from another Fed appointee
Banking
‘They left me no choice’: Powell isn’t going anywhere—blocking Trump from another Fed appointee
By Eva RoytburgApril 29, 2026
19 hours ago
‘Take the money and run’: Johns Hopkins economist Steve Hanke on why the UAE quit OPEC
Energy
‘Take the money and run’: Johns Hopkins economist Steve Hanke on why the UAE quit OPEC
By Shawn TullyApril 29, 2026
1 day ago
More than two-thirds of U.S. schools say they’re unable to afford the cost of student free lunch—and MAHA’s dietary guidelines may make it worse
Economy
More than two-thirds of U.S. schools say they’re unable to afford the cost of student free lunch—and MAHA’s dietary guidelines may make it worse
By Sasha RogelbergApril 29, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.